Lung cancer in women: Role of estrogens

Expert Review of Respiratory Medicine

Volumn 4, Issue 4, 2010, Pages 509-518

  Chakraborty, Subhankar ^a   Ganti, Apar Kishor ^b,c   Marr, Alissa ^b   Batra, Surinder K ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

estrogen; estrogen receptors; fulvestrant; hormone replacement therapy; lung cancer; women

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CETUXIMAB; CISPLATIN; EPIRUBICIN; ERLOTINIB; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EXEMESTANE; FULVESTRANT; GEFITINIB; IFOSFAMIDE; NAVELBINE; TAMOXIFEN;

CANCER INCIDENCE; CANCER RESISTANCE; CARCINOGENICITY; CLINICAL TRIAL; HORMONE SUBSTITUTION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; REVIEW; SMOKING;

EID: 77955027336     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.10.50     Document Type: Review

References (50)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74-108 (2005).
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
3. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin. 56(2), 106-130 (2006).
4. Bray F, Tyczynski JE, Parkin DM. Going up or coming down? The changing phases of the lung cancer epidemic from 1967 to 1999 in the 15 European Union countries. Eur. J. Cancer 40(1), 96-125 (2004).
5. Howe HL, Wingo PA, Thun MJ et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J. Natl Cancer Inst. 93(11), 824-842 (2001).
6. Taioli E, Wynder EL. Re: Endocrine factors and adenocarcinoma of the lung in women. J. Natl Cancer Inst. 86(11), 869-870 (1994).
7. Adami HO, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int. J. Cancer 44(5), 833-839 (1989). (Pubitemid 20007980)
8. Schabath MB, Wu X, Vassilopoulou- Sellin R, Vaporciyan AA, Spitz MR. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin. Cancer Res. 10(1 Pt 1), 113-123 (2004).
9. Ramnath N, Menezes RJ, Loewen G et al. Hormone replacement therapy as a risk factor for non-small cell lung cancer: results of a case-control study. Oncology 73(5-6), 305-310 (2007).
10. Schwartz AG, Wenzlaff AS, Prysak GM et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J. Clin. Oncol. 25(36), 5785-5792 (2007).
11. Chen KY, Hsiao CF, Chang GC et al. Hormone replacement therapy and lung cancer risk in Chinese. Cancer 110(8), 1768-1775 (2007).
12. Koushik A, Parent ME, Siemiatycki J. Characteristics of menstruation and pregnancy and the risk of lung cancer in women. Int. J. Cancer 125(10), 2428-2433 (2009).
13. Moore KA, Mery CM, Jaklitsch MT et al. Menopausal effects on presentation, treatment, and survival of women with non-small cell lung cancer Ann. Thorac. Surg. 76(6), 1789-1795 (2003).
14. Ganti AK, Sahmoun AE, Panwalkar AW, Tendulkar KK, Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J. Clin. Oncol. 24(1), 59-63 (2006).
15. Chlebowski RT, Schwartz AG, Wakelee H et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 374(9697), 1243-1251 (2009).
16. Huang B, Carloss H, Wyatt SW, Riley E. Hormone replacement therapy and survival in lung cancer in postmenopausal women in a rural population. Cancer 115(18), 4167-4175 (2009).
17. Ayeni O, Robinson A. Hormone replacement therapy and outcomes for women with non-small-cell lung cancer: can an association be confirmed? Curr. Oncol. 16(3), 21-25 (2009).
18. Weinberg OK, Marquez-Garban DC, Fishbein MC et al. Aromatase inhibitors in human lung cancer therapy. Cancer Res. 65(24), 11287-11291 (2005).
19. Stabile LP, Davis AL, Gubish CT et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor a and p and show biological responses to estrogen. Cancer Res. 62(7), 2141-2150 (2002).
20. Pietras RJ, Marquez DC, Chen HW, Tsai E, Weinberg O, Fishbein M. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 70(5-7), 372-381 (2005).
21. Marquez-Garban DC, Chen HW, Fishbein MC, Goodglick L, Pietras RJ. Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids 72(2), 135-143 (2007).
22. Deroo BJ, Korach KS. Estrogen receptors and human disease. J. Clin. Invest. 116(3), 561-570 (2006).
23. Kawai H, Ishii A, Washiya K et al. Estrogen receptor a and p are prognostic factors in non-small cell lung cancer. Clin. Cancer Res. 11(14), 5084-5089 (2005).
24. Hershberger PA, Vasquez AC, Kanterewicz B, Land S, Siegfried JM, Nichols M. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res. 65(4), 1598-1605 (2005).
25. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N. Engl. J. Med. 346(5), 340-352 (2002).
26. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor a: a new model for anti-estrogen resistance. J. Biol. Chem. 276(13), 9817-9824 (2001).
27. Chen D, Riedl T, Washbrook E et al. Activation of estrogen receptor a by S118 phosphorylation involves a ligand- dependent interaction with TFIIH and participation of CDK7. Mol. Cell. 6(1), 127-137 (2000).
28. Fasco MJ, Hurteau GJ, Spivack SD. Gender-dependent expression of a and p estrogen receptors in human nontumor and tumor lung tissue. Mol. Cell. Endocrinol. 188(1-2), 125-140 (2002).
29. Pfeffer U, Fecarotta E, Castagnetta L, Vidali G. Estrogen receptor variant messenger RNA lacking exon 4 in estrogen- responsive human breast cancer cell lines. Cancer Res. 53(4), 741-743 (1993).
30. Schwartz AG, Prysak GM, Murphy V et al. Nuclear estrogen receptor p in lung cancer: expression and survival differences by sex. Clin. Cancer Res. 11(20), 7280-7287 (2005).
31. Issa JP, Baylin SB, Belinsky SA. Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Cancer Res. 56(16), 3655-3658 (1996).
32. Hammoud Z, Tan B, Badve S, Bigsby RM. Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. Endocr. Relat. Cancer 15(2), 475-483 (2008).
33. Burger HG. Androgen production in women. Fertil. Steril. 77(SUPPL. 4), S3-S5 (2002).
34. Su JM, Hsu HK, Chang H et al. Expression of estrogen and progesterone receptors in non-small-cell lung cancer: immunohistochemical study. Anticancer Res. 16(6B), 3803-3806 (1996).
35. Kaiser U, Hofmann J, Schilli M et al. Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int. J. Cancer 67(3), 357-364 (1996).
36. Ishibashi H, Suzuki T, Suzuki S et al. Progesterone receptor in non-small cell lung cancer - a potent prognostic factor and possible target for endocrine therapy. Cancer Res. 65(14), 6450-6458 (2005).
37. Raso MG, Behrens C, Herynk MH et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin. Cancer Res. 15(17), 5359-5368 (2009).
38. Mah V, Seligson DB, Li A et al. Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res. 67(21), 10484-10490 (2007)
39. Marquez-Garban DC, Chen HW, Goodglick L, Fishbein MC, Pietras RJ. Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann. NY Acad. Sci. 1155, 194-205 (2009).
40. Chen Y, Perng RP, Yang KY et al. Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy. Lung Cancer 29(2), 139-146 (2000).
41. Chen YM, Perng RP, Yang KY et al. A Phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin combination chemotherapy for inoperable non-small-cell lung cancer. Am. J. Clin. Oncol. 23(1), 13-17 (2000).
42. Traynor AM, Schiller JH, Stabile LP et al. Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer 64(1), 51-59 (2009).
43. Collins IM, Nicholson SA, O'Byrne KJ. A lung cancer responding to hormonal therapy. J. Thorac. Oncol. 5(5), 749-750 (2010).
44. McClay EF, Bogart J, Herndon JE 2nd et al. A Phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). Am. J. Clin. Oncol. 28(1), 81-90 (2005).
45. Blackman JA, Coogan PF, Rosenberg L et al. Estrogen replacement therapy and risk of lung cancer. Pharmacoepidemiol. Drug Saf. 11(7), 561-567 (2002).
46. Kreuzer M, Gerken M, Heinrich J, Kreienbrock L, Wichmann HE. Hormonal factors and risk of lung cancer among women? Int. J. Epidemiol. 32(2), 263-271 (2003). (Pubitemid 36622273)
47. Smith JR, Barrett-Connor E, Kritz-Silverstein D, Wingard DL, Al-Delaimy WK. Hormone use and lung cancer incidence: the Rancho Bernardo cohort study. Menopause 16(5), 1044-1048 (2009).
48. Slatore CG, Chien JW, Au DH, Satia JA, White E. Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J. Clin. Oncol. 28 (9), 1540-1546 (2010).
49. Di Nunno L, Larsson LG, Rinehart JJ, Beissner RS. Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch. Pathol. Lab. Med. 124(10), 1467-1470 (2000).
50. Radzikowska E, Langfort R, Giedronowicz D. Estrogen and progesterone receptors in non small cell lung cancer patients. Ann. Thorac. Cardiovasc. Surg. 8(2), 69-73 (2002).